1、 Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acutemyeloid leukemia: quizartinib and beyond[J]. Ther Adv Hematol, 2014, 5(3):65-77. Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acutemyeloid leukemia: quizartinib and beyond[J]. Ther Adv Hematol, 2014, 5(3):65-77.
2、 Grunwald MR, Levis MJ. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia[J]. Semin Hematol, 2015, 52(3):193-199. Grunwald MR, Levis MJ. FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia[J]. Semin Hematol, 2015, 52(3):193-199.
3、 Bang SM, Ahn JY, Park J, et al. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia[J]. J Korean Med Sci, 2008, 23(5):833-837. Bang SM, Ahn JY, Park J, et al. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia[J]. J Korean Med Sci, 2008, 23(5):833-837.
4、 丁子轩,沈宏杰,缪竞诚,等.C-kit、NPM1、FLT3基因突变在656例中国急性髓系白血病患者中的分布及其对预后的影响[J]. 中华血液学杂志,2012,33(10):829-834. 丁子轩,沈宏杰,缪竞诚,等.C-kit、NPM1、FLT3基因突变在656例中国急性髓系白血病患者中的分布及其对预后的影响[J]. 中华血液学杂志,2012,33(10):829-834.
5、 Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia[J]. Blood,2007, 110:1262-70. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia[J]. Blood,2007, 110:1262-70.
6、 Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients[J]. Blood, 2008, 111: 2527-2537. Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients[J]. Blood, 2008, 111: 2527-2537.
7、 符爽,胡延平,陈芳,等.伴ETO或CBFβ阳性的急性髓细胞白血病患者c-kit基因突变的检测及意义[J]. 现代肿瘤医学,2015,(11):1581-1584. 符爽,胡延平,陈芳,等.伴ETO或CBFβ阳性的急性髓细胞白血病患者c-kit基因突变的检测及意义[J]. 现代肿瘤医学,2015,(11):1581-1584.
8、 叶丽,纪濛濛,孙自敏.急性髓系白血病FLT3基因突变的研究[J]. 中国实验血液学杂志,2015(2):322-327. 叶丽,纪濛濛,孙自敏.急性髓系白血病FLT3基因突变的研究[J]. 中国实验血液学杂志,2015(2):322-327.
9、 Estey E. Why is progress in acute myeloid leukemia so slow[J]. Semin Hematol, 2015, 52(3):243-248. Estey E. Why is progress in acute myeloid leukemia so slow[J]. Semin Hematol, 2015, 52(3):243-248.
